Medication experience and patient's related needs in chronic myeloid leukemia treated with tyrosine kinase inhibitors: Systematic review.

Autor:	Cachafeiro Pin AI; Servicio de Farmacia, Hospital Público da Mariña, Lugo, España. Electronic address: ana.isabel.cachafeiro.pin@sergas.es., Villaverde Piñeiro L; Servicio de Farmacia, Hospital Público de Monforte de Lemos, Lugo, España., Martín Clavo S; Servicio de Farmacia, Hospital Regional Universitario de Málaga, Málaga, España., Silva Castro MM; Vocalía de Investigación, Sociedad Española de Optimización de la Farmacoterapia, Madrid, España.
Jazyk:	English; Spanish; Castilian
Zdroj:	Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria [Farm Hosp] 2023 Mar-Apr; Vol. 47 (2), pp. 85-92. Date of Electronic Publication: 2023 Jan 02.
DOI:	10.1016/j.farma.2022.11.002
Abstrakt:	Objective: Several studies quantitatively described patients with Chronic Myeloid Leukaemia on active treatment with tyrosine kinase inhibitors, however there are few qualitative studies that focus their results on how to accompany patients in the course of the disease over time. The objective of this review is to find out what are the expectations, information needs and experiences that determine adherence to treatment with tyrosine kinase inhibitors in patients with Chronic Myeloid Leukaemia in qualitative research articles published in the scientific literature. Methods: A systematic review of qualitative research articles published between 2003-2021 was carried out in PubMed/Medline, Web of Science and Embase databases. Main keywords used were: "Leukaemia, Myeloid" and "Qualitative Research". Articles on the acute phase or blast phase were excluded. Results: 184 publications were located. After elimination of duplicates, 6 (3%) were included and 176 (97%) publications were excluded. Studies show that the illness is a turning point in patients' lives, and they develop their own strategies for managing the adverse effects. The factors that determine medication experiences with tyrosine kinase inhibitors should be addressed by implementing personalized strategies: this would result in early detection of problems, reinforce education at each stage and promote open discussion about complex causes underlying the treatment failure. Conclusions: This systematic review provides evidence that implementation personalized strategies must be done to adress the factors that determine the illness experience with Chronic Myeloid Leukaemia and receiving treatment with tyrosine kinase inhibitors. (Copyright © 2022 Sociedad Española de Farmacia Hospitalaria (S.E.F.H). Publicado por Elsevier España, S.L.U. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu